MNTA re M118: It’s hard to negotiate a partnership for a drug with big potential when the financial resources of your company could radically change tomorrow, but this is exactly the situation MNTA finds itself in while waiting for the FDA to rule on generic Lovenox.
Craig Wheeler addressed this point on the most recent CC (#msg-46564147).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.